Working… Menu

Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01446497
Recruitment Status : Unknown
Verified October 2011 by Seoul National University Hospital.
Recruitment status was:  Recruiting
First Posted : October 5, 2011
Last Update Posted : October 5, 2011
Information provided by (Responsible Party):
Seoul National University Hospital

Brief Summary:
Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic (Timolol) ophthalmic solutions in normal tension glaucoma patients.

Condition or disease Intervention/treatment Phase
Normal Tension Glaucoma Drug: Brimonidine/Timolol mixed combination Drug: Timolol Phase 4

Detailed Description:
  • Normal tension glaucoma (NTG) is the major type of glaucoma in Korea. (over 90% of glaucoma type)
  • Brimonidine (selective alpha 2 adrenergic agonist): neuroprotection effect by suppression of aqueous humor production and increasement of uveoscleral outflow
  • Timolol (non selective beta blocker): suppression effect of aqueous humor production
  • Combigan (fixed combination of brimonidine & timolol): more lowering effect of intraocular pressure and enhancing the compliance of glaucoma patients

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients
Study Start Date : October 2010
Actual Primary Completion Date : August 2011
Estimated Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Active Comparator: Timolol
non selective beta blocker, aqueous humor suppressant ophthalmic solution
Drug: Brimonidine/Timolol mixed combination
Twice per day, 1 drop at each time
Other Name: Combigan

Active Comparator: Combigan (Timolol/Brimonidine) combination drug
Brimonidine: alpha-2 agonist
Drug: Timolol
Twice per day, 1 drop at each time
Other Name: Timoptic XE

Primary Outcome Measures :
  1. Change from baseline in intraocular pressure at 12 weeks [ Time Frame: 12 weeks after the initial treatment ]
    Intraocular pressure (IOP) check by Goldmann applanation tonometry with topical anesthetic eyedrop

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • over 18 years old
  • baseline IOP under 22 mmHg,both anterior chamber angle > Grade 3~4 by Shaffer grading system

Exclusion Criteria:

  • IOP over 22 mmHg by Goldmann applanation tonometer
  • other types of glaucoma except open angle
  • other IOP lowering treatment
  • chronic or recurrent Hx. of ocular inflammation
  • using contact lens
  • any other ocular disease that could affect visual field examination (diabetic retinopathy, macular disease, uveitis, scleritis, optic neuritis, anterior ischemic optic neuropathy)
  • intraocular or glaucoma surgery within 6 months
  • Hx. of allergic reaction to timolol or brimonidine
  • bronchial asthma
  • moderate to severe chronic obstructive pulmonary disease
  • heart failure
  • 2~3 degree A-V block,
  • MAO inhibitor use
  • anti depressant use
  • untreated pheochromocytoma
  • pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01446497

Layout table for location contacts
Contact: Ki Ho Park, M.D., Ph.D. +82-2-2072-2438 ext 3172
Contact: Jae Hoon Jeong, M.D. +82-2-2072-2438 ext 3110

Layout table for location information
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Ki Ho Park, M.D., Ph.D.    +82-2-2072-2438 ext 3172   
Contact: Jae Hoon Jeong, M.D.    +82-2-2072-2438 ext 3110   
Sponsors and Collaborators
Seoul National University Hospital
Layout table for investigator information
Principal Investigator: Ki Ho Park, M.D, Ph.D. Seoul National University Hospital

Layout table for additonal information
Responsible Party: Seoul National University Hospital Identifier: NCT01446497     History of Changes
Other Study ID Numbers: H-1008-059-327
KHP01 ( Registry Identifier: SNUH )
First Posted: October 5, 2011    Key Record Dates
Last Update Posted: October 5, 2011
Last Verified: October 2011
Keywords provided by Seoul National University Hospital:
Normal tension glaucoma
Antiglaucoma ophthalmic solution
Combination drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Brimonidine Tartrate
Brimonidine Tartrate, Timolol Maleate Drug Combination
Low Tension Glaucoma
Ocular Hypertension
Eye Diseases
Optic Nerve Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists